Drilldown: Medicines

Other values:

Search

None (78) · Coreg, Coreg CR (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · GABAA positive allosteric modulator (18) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Contains LSA (2) · Contains mescaline (2)

Other values:

Search

None (92) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (92) · 0.25 mg (1) · Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID (1)

None (92) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · IR tablets 3.125, 6.25, 12.5, 25 mg; Coreg CR capsules 10, 20, 40, 80 mg (once-daily) (1)

None (92) · 10 mg/d (1) · 50 mg BID in heart failure (or once-daily equivalent CR); 25 mg BID in hypertension (1)

None (91) · Oral (3)

None (91) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 minutes (1) · Antihypertensive effect within 1 week; heart-failure mortality benefit accrues over months of titration (1)

None (91) · 6 h (immediate-release); ~11 h (extended-release) (1) · 8–12 hours (1) · ~12 hours (IR); 24 hours (CR) (1)

None (91) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3–5 hours (1) · 7-10 hours'"`UNIQ--ref-0000001B-QINU`"' (1)

None (91) · 70–90% (oral) (1) · 80-90% oral (1) · ~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"' (1)

None (91) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)

None (91) · Schedule I (United States) (1) · Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)